Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.
about
Non-muscle myosin II in disease: mechanisms and therapeutic opportunitiesThe pathogenesis of chronic lymphocytic leukemiaProtective natural autoantibodies to apoptotic cells: evidence of convergent selection of recurrent innate-like clonesB-cell receptor signalling and its crosstalk with other pathways in normal and malignant cellsStereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells.Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells.Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLLMany chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of originB-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia.Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia.Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapyBruton's tyrosine kinase (BTK) inhibitors in clinical trials.High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors.B-cell receptor signaling as a driver of lymphoma development and evolution.Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin LymphomaInhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.An entity evolving into a community: defining the common ancestor and evolutionary trajectory of chronic lymphocytic leukemia stereotyped subset #4.Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8.Partial versus productive immunoglobulin heavy locus rearrangements in chronic lymphocytic leukemia: implications for B-cell receptor stereotypyEnhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells.Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen.Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L.Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.The Number of Overlapping AID Hotspots in Germline IGHV Genes Is Inversely Correlated with Mutation Frequency in Chronic Lymphocytic Leukemia.Molecular pathogenesis of chronic lymphocytic leukemia.Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLLSelf-antigen recognition by follicular lymphoma B-cell receptors.Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors.Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigenBTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia.Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation.Combined patterns of IGHV repertoire and cytogenetic/molecular alterations in monoclonal B lymphocytosis versus chronic lymphocytic leukemiaB-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.Temporal dynamics of clonal evolution in chronic lymphocytic leukemia with stereotyped IGHV4-34/IGKV2-30 antigen receptors: longitudinal immunogenetic evidence.Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells.The microenvironment in mature B-cell malignancies: a target for new treatment strategies
P2860
Q26778962-5F83C43C-F96F-4248-827F-A4254D5125CEQ27025715-50B316CA-4A74-4740-99F5-0B770704D1DFQ28081863-629B1E47-1803-4334-B1DE-1FB819E65538Q28245018-A30277B9-9EA4-4075-A41E-CA7024DEBB5BQ30994095-38176A6C-EAE6-47D9-B4E2-062D88F29A6EQ33350258-CDE10EC6-AFB6-4D4E-A0A9-A688E3C96C27Q33494799-73A08E60-9B18-460C-B5B9-339AFA271E51Q33714712-9DCF7ABF-561F-4864-932F-61A1B28E45C2Q33849548-9058F849-7AC4-4651-B93B-CDD8FB5D90DFQ33878649-B90EAE8F-46DB-4346-A64D-178821FF3E40Q33886052-D5A36C0F-825E-4A33-87FC-397E3AFEDD40Q34020276-65BE5A79-F4F6-40B1-AA15-C687259B2715Q34039406-EAF54B90-683F-465C-8318-E09A9363F791Q34095630-9EF95A32-0612-4A9D-917E-E8EB88AF541DQ34398579-AA0260E3-0682-4E70-ADBF-3615B046BC18Q34534572-D053D846-B36F-4F1B-8E57-E3525C334C8FQ35096709-5B8A74CC-FC20-4B3F-A62C-21BB63B52264Q35153215-E3746D72-7B7C-4D00-8099-C4CE6EDCE72FQ35434973-FD8A4FA9-420E-4932-9400-773A4C871D7FQ35692395-F5B12833-7F96-4D2F-AB63-635063EFB5F5Q35747546-3DCE52F0-3257-4D00-AEC8-3E4F3B24BA62Q35777015-A41D8844-4015-4F56-9379-1229A86B4ECEQ35849244-F23991D0-8B4C-4545-98B7-4811A4A313BBQ36016378-7400C26C-17E1-4067-A6FA-9471FFB75AB1Q36083000-B37D2E9D-6704-4521-BBE9-7496233205F9Q36261329-718430FD-F655-4939-ACC8-4EAD4FB73E2FQ36290321-0CCC8CF3-2227-4B35-B359-5D2AD6F0C4ABQ36404778-D46FFB10-062A-4574-A3A4-4F9C52A627A7Q36410149-A8734B90-C6E8-4231-B1E9-58A075A0550CQ36462375-B0785C8C-C210-4C27-BA01-0A7C68F38317Q36465271-0FC57F93-25BA-4D09-8685-F818D9FFEA2BQ36788328-5628B143-8D61-4CB6-ADFA-4C877A44BAE4Q36799197-A324C641-7239-4277-90CA-C5BE4C90970DQ36862781-7238FE81-232C-42B4-A4ED-8F3ADADC1208Q36972595-D7064C26-24F0-47A6-9AE0-CAEE88ABDB02Q36981193-D669FF63-1CCF-427A-9FD2-2F2316D9363FQ37028635-E7C4CE9F-47D9-43DE-9D3E-D7455B10716FQ37161516-658D2B96-E700-4201-82BF-350EC0270DC2Q37164030-FF72CCDB-E9B2-44C4-91B2-5E0D2688868AQ37563816-00AE501D-7FC8-4D29-8978-8476BED9185D
P2860
Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chronic lymphocytic leukemia a ...... muscle myosin heavy chain IIA.
@en
Chronic lymphocytic leukemia a ...... muscle myosin heavy chain IIA.
@nl
type
label
Chronic lymphocytic leukemia a ...... muscle myosin heavy chain IIA.
@en
Chronic lymphocytic leukemia a ...... muscle myosin heavy chain IIA.
@nl
prefLabel
Chronic lymphocytic leukemia a ...... muscle myosin heavy chain IIA.
@en
Chronic lymphocytic leukemia a ...... muscle myosin heavy chain IIA.
@nl
P2093
P2860
P921
P1433
P1476
Chronic lymphocytic leukemia a ...... muscle myosin heavy chain IIA.
@en
P2093
Charles C Chu
Henry M Fales
Jonathan E Kolitz
Kanti R Rai
Katerina Hatzi
Nicholas Chiorazzi
Rosa Catera
Xiao Bo Wang
Xiao-Jie Yan
P2860
P304
P356
10.1182/BLOOD-2008-06-162024
P407
P50
P577
2008-09-23T00:00:00Z